 Kintara Therapeutics Inc NASDAQ:KTRA FRA:3DM announced it has enrolled the final patient in the adjuvant arm of its ongoing Phase 2 clinical study of VAL-083 as a treatment for glioblastoma multiforme GBM, a cancer that begins in the brain. The adjuvant arm of the study, conducted at the MD Anderson Cancer Center in Austin, has patients receive VAL-083 in place of standard-of-care temozolomide TMZ following surgery and chemoradiation TMZ. 